Chloracne-like drug eruption associated with sorafenib

Journal of Drugs in Dermatology

Volumn 10, Issue 11, 2011, Pages 1331-1334

  Pickert, Amanda ^a   Hughes, Michele ^a   Wells, Michael ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,5 TRICHLOROPHENOXYACETIC ACID; ACETYLSALICYLIC ACID; AROMATIC HYDROCARBON; BENZOYL PEROXIDE; CODEINE; LISINOPRIL; METRONIDAZOLE; MORPHINE SULFATE; PARACETAMOL; RETINOIC ACID; SALBUTAMOL; SORAFENIB; VERAPAMIL;

ADULT; ARTICLE; BURNING SENSATION; CANCER RADIOTHERAPY; CHLORACNE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; NEPHRECTOMY; OILY SKIN; PATIENT COMPLIANCE; PRURITUS; RASH; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHLORACNE; DRUG ERUPTIONS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES;

EID: 80655128192     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
2. Ahmad T, Eisen T. Kinase inhibition with Bay43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10:6388S-6392S. (Pubitemid 39302607)
3. Autier J, Escudier B, Wechsler J, et al. Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor. Arch Dermatol. 2008;144(7):886-892. (Pubitemid 352039741)
4. Hambrick GW. The effect of substituted naphthalenes on the pilosebaceous apparatus of rabbit and man. J Invest Dermatol. 1957;28:89-103.
5. Dunagin WG. Cutaneous signs of systemic toxicity due to dioxins and related compounds. J Am Acad Dermatol. 1984;10:688-700. (Pubitemid 14171249)
6. Tindall JP. Chloracne and chloracnegens. J Am Acad Dermatol. 1985;13:539-558. (Pubitemid 15246634)
7. Jensen NE, Sneddon IB, Walker AE. Tetrachlorobensodioxin and chloracne. Trans St Johns Hosp Dermatol Soc. 1972;58:172-177.
8. Panteleyev AA, Bicker DR. Dioxin-induced chloracne-reconstructing the cellular and molecular mechanism of a classic environmental disease. Exp Dermatol. 2006:15;705-730. (Pubitemid 44145241)
9. Pastor MA, Carrasco L, Izquierdo MJ, et al. Chloracne: Histopathologic findings in one case. J Cutan Pathol. 2002;29:193-199. (Pubitemid 34615373)
10. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512. (Pubitemid 46630627)
11. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008;58:545-574.
12. Strumberg D, Seeber S. Raf Kinase inhibitors in oncology. Onkologie. 2005;28:101-107. (Pubitemid 40292043)
13. Carlomagn F, Anaganti S, Guidt, et al. Bay43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326-334.
14. Wihelm SM, Carter C, Tang L, et al. Bay43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
15. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006;31:783-785. (Pubitemid 44563396)
16. Dasanu C, Dutcher J, Alexandrescu D. Yellow skin discoloration associated with Sorafenib use for treatment of metastatic renal cell carcinoma. South Med J. 2007;100:328-330. (Pubitemid 46673440)
17. MacGregor J, Silvers D, Grossman M, et al. Sorafenib induced erythema multiforme. J Am Acad Dermatol. 2007;56:527-523.
18. Kong H, Cowen E, Azad N, et al. Keratoacanthomas associated with sorefenib therapy. J Am Acad Dermatol. 2007;56:171-172.
19. Kong HH, Sibaud V, Chanco Turner ML, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820-822. (Pubitemid 351846901)
20. Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008;144(6):779-782. (Pubitemid 351846880)
21. Lountzis NI, Maroon MS. Sorafenib-induced palmoplantar hyperkeratosis. J Drugs Dermatol. 2008;7(6):588-589.
22. Lacouture ME, Basti S, Patel J, et al. The SERIES clinic: An interdisciplinary approach to the manangement of toxicities of EGFR inhibitors. J Support Oncol. 2006;4:236-238.
23. Strumberg D, Awanda A, Hirte H, et al. Pooled safety analysis of Bay43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: Is rash associated with treatment outcomes? Eur J Cancer. 2006;42:548-556. (Pubitemid 43227936)